


Attorney Docket No.: 5390.200-US

PATENT

#5  
9/21/00  
SW



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Dörwald et al.

Application No.: 09/548,081

Group Art Unit: 1594

Filed: April 12, 2000

Examiner: TBA

For: Substituted Imidazoles, their Preparation and Use

RECEIVED

SEP 20 2000

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, DC 20231

TECH CENTER 1600/2900

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. Krause et al., J. Med. Chem., Vol. 38, pp. 4070-4079 (1995)

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of

record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of the application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. § 1.97(b). Therefore, no fee is due.

Respectfully submitted,

Date: September 11, 2000

---

Carol E. Rozek, Reg. No. 36,993  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123



Attorney Docket No.: 5390.200-US

GAU: 1594  
1624

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re Application of: Dörwald et al.

SEP 20 2000

Application No.: 09/548,081

Group Art Unit: 1594

Filed: April 12, 2000

Examiner: TBA

TECH CENTER 1600/2900

For: Substituted Imidazoles, their Preparation and Use

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:


1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents  
Washington, DC 20231

on September 11, 2000.

Miriam Kelly  
(name of person mailing paper)

  
(signature of person mailing paper)